Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation.

@article{Pennati2005PotentiationOP,
  title={Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation.},
  author={Marzia Pennati and A. M. Campbell and Maria Jo{\~a}o Marcelo Curto and Mara Binda and Yuzhu Cheng and Lan-Zeng Wang and Nicola J Curtin and Bernard T Golding and Roger J. Griffin and Ian R. Hardcastle and Andrew Henderson and Nadia Zaffaroni and David R. Newell},
  journal={Molecular cancer therapeutics},
  year={2005},
  volume={4 9},
  pages={1328-37}
}
Cyclin-dependent kinases (CDK) play a crucial role in the control of the cell cycle. Aberrations in the control of cell cycle progression occur in the majority of human malignancies; hence, CDKs are promising targets for anticancer therapy. Here, we define the cellular effects of the novel CDK inhibitor NU6140, alone or in association with paclitaxel, with respect to inhibition of cell proliferation and cell cycle progression and induction of apoptosis in HeLa cervical carcinoma cells and in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

Similar Papers

Loading similar papers…